实时热点！魔兽世界怀旧服国服测试开启：6月11日重返艾泽拉斯

魔兽世界怀旧服国服测试开启：6月11日重返艾泽拉斯

北京时间2024年6月6日讯，网易今日宣布，《魔兽世界》国服“巫妖王之怒”怀旧服将于6月11日开启删档技术测试。本次测试将对所有玩家开放，不限号。测试期间将开设专属测试服务器“抗压一号”与“抗压二号”，服务器将在每日上午11:00至晚上23:00限时开放。测试期间玩家账号内的游戏时间不会消耗，所有测试角色将在测试结束后删除。

本次测试主要目的是为了检验服务器的负载能力以及游戏内容的稳定性，为“巫妖王之怒”怀旧服的正式上线做准备。测试内容包括：

• 从1级至70级的完整游戏内容
• 所有开放的地下城和团队副本
• 部分PvP战场
• 部分专业技能

玩家可以通过战网客户端下载“巫妖王之怒”怀旧服客户端，并提前创建角色。测试期间，玩家可以在测试服务器上体验游戏内容，并提出反馈意见。

“巫妖王之怒”是《魔兽世界》的第二部资料片，于2008年发行。资料片以北极大陆为主要舞台，讲述了玩家对抗巫妖王阿尔萨斯的故事。资料片内容丰富，玩法多样，被认为是《魔兽世界》历史上最成功的资料片之一。

此次“巫妖王之怒”怀旧服的推出，将让玩家重温经典的游戏内容，体验当年开荒的乐趣。网易表示，他们将尽力还原当年游戏的内容和体验，为玩家带来原汁原味的怀旧体验。

以下为本次测试的几点注意事项：

• 玩家每天只能在每个测试服务器上创建1个角色。
• 角色等级上限为70级。
• 测试期间获得的所有游戏道具和金币将在测试结束后清空。
• 玩家可以在测试服务器上进行游戏截图和录像，但请勿泄露测试服务器的任何信息。

网易希望所有玩家都能积极参与本次测试，并提出宝贵意见，帮助他们完善“巫妖王之怒”怀旧服。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.